Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

Exclusion Criteria

• •Pregnant or breastfeeding women
• •Positive for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab)
• •HCV genotype of any subtype other than GT1a or unable to subtype
• •Prior or current use of any investigational or commercially available anti-HCV agents other than IFN, pegIFN or RBV. Subjects with previous participation in trials of investigational direct-acting antiviral agents (DAAs) may be enrolled if they can produce documentation that they received only placebo.
• •Current enrollment in another interventional clinical study or receipt of any investigational product within 6 weeks prior to study drug administration.